Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    21756035 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma
Conditions: Leukemia;   Lymphoma
Interventions: Biological: pegfilgrastim;   Biological: rituximab;   Drug: cyclophosphamide

Indicates status has not been verified in more than two years